Overview

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)
Phase:
Phase 3
Details
Lead Sponsor:
Viridian Therapeutics, Inc.